Last updated: April 23, 2026
Who supplies ofloxacin API and finished-dose products?
Ofloxacin is a widely manufactured fluoroquinolone antibiotic with global coverage across API producers and finished-dose manufacturers. Supply typically comes from:
- API makers producing ofloxacin bulk drug substance for generic formulators.
- Finished-dose manufacturers producing tablets (including 100 mg and 200 mg strengths) and, in some markets, ophthalmic formulations.
In practice, companies source ofloxacin through:
- Global generic networks that purchase API and do formulation/packaging under their own labels.
- Direct API supply arrangements from API manufacturers with validated quality systems and regulatory support.
Which markets and product forms drive supplier demand?
Demand concentrates in three use cases:
- Oral tablets (common generic segment across hospital and retail procurement).
- Ophthalmic products (where ofloxacin is used for eye infections; supply can differ by country).
- Hospital procurement channels that require consistent batch release documentation, stability data, and controlled change management.
How do supplier categories map to procurement decisions?
Procurement teams typically separate suppliers by capability:
| Supplier category |
Typical products |
What procurement verifies |
| API producers |
Ofloxacin API (bulk drug substance) |
ASR/DMF availability, impurity profile, CoA consistency, GMP status, change notifications |
| Finished-dose manufacturers |
Ofloxacin tablets and sometimes ophthalmic products |
finished product dossier support, stability, packaging compliance, labeling/traceability |
| Specialty distributors |
Supply of API or finished product |
temperature/logistics controls (where applicable), chain of custody, lead times |
What regulatory documentation shapes supplier qualification?
Qualification commonly depends on:
- Drug Master File (DMF) or equivalent API regulatory file availability for API producers (where used in target geographies).
- GMP inspection history for API and finished-dose sites.
- Pharmacopoeia compliance (commonly BP/USP/EP expectations depending on market).
- Quality agreements that define batch testing, impurities, reference standards, and stability commitments.
What supplier landscape usually exists for ofloxacin?
The ofloxacin supply market is characterized by:
- High generic density: multiple manufacturers produce ofloxacin tablets and often the API.
- Regional variability: some suppliers are strong in specific geographies due to dossier readiness and local manufacturing footprints.
- Multiple grade handling: API and finished-dose supply may require different documentation packs by market.
Which supplier types are most reliable for recurring procurement?
For sustained procurement, the lowest execution risk typically comes from suppliers that can deliver:
- Repeatable batch release with consistent CoA parameters (assay, impurities, residue solvents where applicable).
- Document continuity: stable impurity methods and reference standards.
- Clear manufacturing change control that supports regulatory notifications and reduces dossier friction.
Key procurement checklist for selecting an ofloxacin supplier
Use this checklist to screen suppliers in a data-backed way:
| Qualification dimension |
Evidence to require |
| Regulatory readiness |
DMF or dossier linkages for API; full regulatory package for finished-dose products |
| Quality system |
GMP certificate for relevant sites; inspection outcomes |
| Chemistry and analytics |
Impurity profile method equivalence; batch CoA for recent lots |
| Supply continuity |
Minimum order quantities, lead times, allocation policy |
| Change control |
Documented process for notifying formulation or API changes |
| Packaging and compliance |
Labeling specs, traceability, serialization where required |
Key takeaways
- Ofloxacin supply is dominated by generic API and finished-dose manufacturing, with supplier qualification driven by DMF/dossier readiness, GMP history, and CoA consistency.
- Procurement reliability improves with suppliers that provide repeatable batch data, stable quality standards, and strong change control.
- For recurring programs, focus on API producers with established regulatory pathways and finished-dose makers with dossier and packaging compliance in the target market.
FAQs
-
Is ofloxacin API supplied by the same companies that sell finished-dose products?
Often no. API makers and finished-dose manufacturers frequently operate as different entities with different regulatory packs.
-
What documentation matters most when qualifying an ofloxacin API supplier?
GMP evidence, DMF (or equivalent dossier support), recent CoAs, impurity methodology, and stability expectations.
-
Which dosage forms have the most consistent sourcing?
Oral tablets generally have the broadest manufacturing footprint across generic markets.
-
How do impurities affect supplier selection for ofloxacin?
Impurity profiles and analytical method consistency directly impact lot release, regulatory acceptance, and interchangeability.
-
What typically increases supplier execution risk?
Unclear change control, inconsistent CoA parameters across lots, weak dossier continuity, and unstable lead times.
References
[1] U.S. Food and Drug Administration. Drug Master Files (DMF) information. FDA. https://www.fda.gov/drugs/dmfs
[2] European Medicines Agency. GMP and inspections. EMA. https://www.ema.europa.eu/en/human-regulatory/research-development/good-manufacturing-practice/gmp-inspections
